Centene Corporation (CNC)
NYSEHealth CareHealthcare PlansSnapshot 2026-07-08
$67.06+1.42%
Close 2026-07-08 · 1-day change
Reading CNC? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track CNC free→NYSEHealth CareHealthcare PlansSnapshot 2026-07-08
Reading CNC? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track CNC free→QuarterlyIQ Insights · CNC
Price, fair value, and the multiples that frame it on the same time axis. Scroll over the price chart to zoom.
Daily closes. Earnings/event dots inline.
A consensus fair price across 11 valuation methods, at three horizons. Current price $67.06. As of 2026-07-08. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A long-thesis check that carries the widest uncertainty of the three horizons.
Below average on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $66 CNC trades at 26× p/e, below its 27× p/e peer median, but our blended $61 fair value sits below the price. We hold it with medium confidence: it trades at 1.7× its own p/e history. Analysts target $39–$80. Not investment advice.
$39.00 – $80.00 (median $60.00) · 17 analysts · as of 2026-07-07
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
No fragility gates fired. Regime (Mania) does not concentrate fragility.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
These describe the expectations embedded in the price, not a forecast of the move. Reverse-DCF base: $8.30/sh owner earnings.
Roughly priced in line with peers.
Richer than its own typical valuation.
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
Score 100 = cheapest in the cohort, 0 = richest. Bars are filled left-to-right based on the peer-relative score (or PEG/self-history where shown).
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Each method's implied share price per horizon. Provisional rows use a projected (historical-CAGR) growth input rather than analyst or management guidance.
| Method | Horizon | Est. price | Multiple | Per-share input | EPS source | Confidence |
|---|---|---|---|---|---|---|
| analyst target | 12M | $60.00 | — | — | Analyst | high |
| dcf fcfe | 12M | $126.16 | — | — | Hist. CAGR | high |
| dcf fcff | 12M | $167.19 | — | — | Hist. CAGR | high |
| graham number | 12M | $49.60 | — | — | TTM | high |
| Mgmt guidance | 12M | $52.50 | 26.3 | 2.00 | Mgmt | high |
| Peer P/FCF | 12M | $255.13 | 19.9 | 12.80 | TTM | high |
| Peer P/E | 12M | $66.15 | 26.3 | 2.52 | TTM | high |
| PEG | 12M | $106.37 | 42.2 | 2.52 | TTM | high |
| residual income | 12M | $38.52 | — | — | TTM | high |
| Own P/E history | 12M | $39.49 | 15.7 | 2.52 | TTM | high |
| triangulated | 12M | $72.47 | 26.3 | 2.76 | Triangulated | high |
| Mgmt guidance | 3Y | $167.86 | 26.3 | 6.39 | Mgmt(prov.) | medium |
| Peer P/FCF | 3Y | $192.93 | 19.9 | 9.68 | Hist. CAGR(prov.) | medium |
| Peer P/E | 3Y | $129.16 | 26.3 | 4.92 | Analyst | medium |
| PEG | 3Y | $207.68 | 42.2 | 4.92 | Analyst | medium |
| Own P/E history | 3Y | $77.10 | 15.7 | 4.92 | Analyst | medium |
| Mgmt guidance | 5Y | $364.31 | 26.3 | 13.88 | Mgmt(prov.) | medium |
| Peer P/FCF | 5Y | $160.14 | 19.9 | 8.04 | Hist. CAGR(prov.) | medium |
| Peer P/E | 5Y | $92.89 | 26.3 | 3.54 | Analyst | medium |
| Peer P/S | 5Y | $566.13 | 3.2 | 175.34 | guidance | medium |
| PEG | 5Y | $149.37 | 42.2 | 3.54 | Analyst | medium |
| Own P/E history | 5Y | $55.45 | 15.7 | 3.54 | Analyst | medium |
A “consensus-then vs. actual-now” overlay is on the way — what our valuation estimate said on a past date versus where the price actually landed.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.